Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780
Debt
Debt-to-Equity Ratio0.41
Current Ratio5.39
Quick Ratio4.86
Price-To-Earnings
Trailing P/E Ratio-11.54
Forward P/E Ratio-17.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$103.08 million
Price / Sales4.08
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book4.74
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-23.41%
Return on Equity-39.85%
Return on Assets-23.41%
Miscellaneous
Employees437
Outstanding Shares25,970,000
Market Cap$421.45 million
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings results on Tuesday, July, 31st. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). The company had revenue of $29.32 million for the quarter, compared to analyst estimates of $28.58 million. Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The firm's revenue was up 12.3% on a year-over-year basis. During the same period last year, the firm earned ($0.74) earnings per share. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
4 brokerages have issued twelve-month price objectives for Oxford Immunotec Global's stock. Their predictions range from $15.00 to $20.00. On average, they expect Oxford Immunotec Global's share price to reach $18.25 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.
What is the consensus analysts' recommendation for Oxford Immunotec Global?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF) and Fluoropharma Medical (FPMI).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
- Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $16.20.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $421.45 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 437 workers across the globe.
What is Oxford Immunotec Global's official website?
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
